Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » CareDx, Veracyte to Commercialize Organ Transplant Rejection Tests on nCounter Platform

CareDx, Veracyte to Commercialize Organ Transplant Rejection Tests on nCounter Platform

May 14, 2020
|
staff reporter

NEW YORK – CareDx and Veracyte said on Thursday that they have signed an agreement to make CareDx the exclusive worldwide commercialization partner for solid organ transplant rejection tests on Veracyte's nCounter Flex Analysis diagnostic platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Swabs for Science of Spread

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

Genome of the Murder Hornet

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

In a Pool Together

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

Science Presents Paper on Computational Method to Predict IBD Patient Response to Therapy

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.

What's Popular?

In Business News

  1. Illumina Q2 Revenues Drop 25 Percent

  2. Blackstone to Acquire Ancestry for $4.7B

  3. Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

  4. Rakuten Medical Sues Illumina Over Trademark Dispute

  5. Twist Bioscience Q3 Revenues Grow 56 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.